FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through a link in this article, a commission may be earned at no additional cost to you. This does not influence editorial content.
The New York Times profile of MEDVi on April 2, 2026 sent shockwaves through the telehealth industry — and a flood of consumers to Google trying to figure out where this company came from and whether it is the right choice for them. Matthew Gallagher's story — $20,000, two employees, $401 million in first-year revenue, a projected $1.8 billion for 2026 — is unlike anything the GLP-1 market has seen. But the viral growth story landed alongside an FDA warning letter, a 1.6-million-patient data breach at MEDVi's clinical partner OpenLoop Health, and pending litigation that raises questions about compounded oral tirzepatide efficacy.
For consumers, the MEDVi headlines create an obvious question: how does this company actually compare to established alternatives like Hims, Ro, and Henry Meds? Not in terms of which one is trending on social media — but in terms of what you pay, what you receive, and how much regulatory risk you carry as a patient.
This comparison lays it out by the factors that actually matter.
The Context: Why This Comparison Matters Right Now
Before the numbers, the context. The telehealth GLP-1 market is under more regulatory pressure in April 2026 than at any point in its history. The FDA issued warning letters to more than 30 telehealth companies in March 2026 for misleading marketing of compounded GLP-1 products. Drug shortages that originally justified expanded compounding are beginning to ease. Novo Nordisk has filed a patent infringement lawsuit against Hims. The rules underneath this entire market are shifting.
MEDVi's sudden fame — courtesy of the NYT profile — has made it the most visible company in a market where visibility attracts regulatory attention. That does not mean MEDVi is worse than its competitors. It means consumers should understand how each provider is positioned relative to the same market pressures.
Pricing: What You Actually Pay
MEDVi: Compounded semaglutide at $179 first month, $299 per month refills. Compounded tirzepatide at $349 per month. Oral tablets at $249. Brand-name Wegovy/Zepbound through $99 membership plus medication cost. Cash-pay, no insurance. A March 2026 pricing evaluation published through Globe Newswire examined MEDVi's positioning as the most affordable tirzepatide provider in the telehealth GLP-1 market based on publicly available pricing data.
Hims & Hers: Compounded semaglutide starting around $199 per month. Brand-name Wegovy also available. Publicly traded, has run promotional pricing. Check current rates — they shift.
Ro: Branded Wegovy at $199 first two months, then $349 per month. Compounded options also available. Clearly separates brand-name and compounded product lines.
Henry Meds: Compounded semaglutide at $197 to $297 per month depending on dosage. Focused on compounded products.
The takeaway: MEDVi wins on first-month price ($179). The ongoing $299 narrows the gap. The cheapest option is not always the best option — what comes with that price matters just as much.
Medication: Compounded vs. Brand-Name Options
MEDVi: Built primarily on compounded products. Recently added brand-name Wegovy and Zepbound paths, but compounded remains the flagship.
Hims: Offers both compounded and FDA-approved branded options. More established with both lines.
Ro: Offers both paths. Does the best job of clearly separating the two so patients can make an informed choice. Best option if FDA-approved medication is your priority.
Henry Meds: Focused on compounded products. Does not prominently offer brand-name paths.
The clinical distinction: compounded GLP-1 medications are not FDA-approved as finished products. They contain the same active ingredients as branded drugs but are prepared by compounding pharmacies with different quality assurance standards. Brand-name Wegovy and Zepbound have gone through full clinical trials. Both Ro and Hims offer clearer paths to branded medication.
Regulatory Status: Where Each Company Stands
MEDVi: FDA warning letter (February 2026) for misbranding. One of 30-plus companies warned. Clinical partner OpenLoop has a data breach and class-action litigation. Active LegitScript certification. NYT-verified financials. Two employees.
Hims: Patent infringement lawsuit from Novo Nordisk. Publicly traded with SEC reporting requirements and larger compliance operation. No comparable FDA misbranding warning as of April 2026.
Ro: No major GLP-1-specific regulatory actions publicly reported. Emphasis on brand-name medication may reduce exposure to compounding enforcement.
Henry Meds: Not publicly named in major enforcement actions. Lower profile means less public information about regulatory standing.
Every company selling compounded GLP-1s faces the same regulatory uncertainty. MEDVi is the most scrutinized because of the NYT story. The underlying pressures — shortage resolution, FDA enforcement escalation, patent litigation — affect the entire market.
Clinical Infrastructure: Who Provides Your Care
MEDVi: Uses OpenLoop Health and CareValidate for all clinical services. Two total employees. OpenLoop's January 2026 data breach is a real concern for patients.
Hims: Internal clinical infrastructure with employed and contracted providers. Over 2,400 employees. More traditional clinical operations.
Ro: Operates its own clinical network. Invested in building internal infrastructure rather than relying on third-party platforms.
Henry Meds: Partner-based model similar to MEDVi but at smaller scale.
The trade-off: Hims and Ro control more of the clinical chain internally. MEDVi and Henry Meds outsource it. Neither approach is automatically safer, but the three-party model means a data breach or lawsuit at an infrastructure partner affects every consumer brand on that platform.
Customer Experience: What Review Data Shows
MEDVi: Trustpilot 4.4-4.5 out of 5 (11,400+ reviews). ConsumerAffairs 3.6 out of 5 (~1,600 reviews). Dominant complaint pattern: auto-renewal billing confusion, cancellation difficulty, refund disputes. 72-hour cancellation window.
Hims: Trustpilot ~4.0 out of 5 across a large base. More mature customer service. Fewer billing-specific complaints than MEDVi.
Ro: Generally positive. Fewer billing complaints. More transparent subscription model.
Henry Meds: Smaller volume. Fewer billing complaints in available data.
If billing transparency and easy cancellation are priorities, Ro and Henry Meds currently have better reputations in those areas. MEDVi's growth appears to have outpaced its customer service infrastructure.
Who Each Provider Fits Best
MEDVi if: Lowest entry price is your top priority, you understand compounded medications, you have read the billing terms, and you are comfortable with the current regulatory situation.
Hims if: You want both compounded and brand-name options from a publicly traded company with a longer track record and larger support operation.
Ro if: FDA-approved medication is your priority, you value billing transparency, and you want the clearest separation between compounded and branded product lines.
Henry Meds if: You want competitive compounded pricing with fewer reported billing complaints and do not need brand-name options.
The Bigger Picture
The MEDVi story has done something valuable for consumers: it forced the entire telehealth GLP-1 market into the spotlight. The NYT profile, the FDA warnings, the data breach, the lawsuits — these are not just MEDVi issues. They reflect the state of an industry that grew faster than its regulatory framework could keep pace with.
Whatever provider you choose, talk with your own doctor first. Understand what compounded medication means. Read the billing terms. And stay aware that the regulatory ground beneath every compounded GLP-1 program may shift during the course of your treatment.
Frequently Asked Questions
Which telehealth GLP-1 provider is cheapest?
MEDVi at $179 first month for compounded semaglutide. Henry Meds starts at $197. Hims at $199. Ro at $199-$349 for branded Wegovy. MEDVi's refill price of $299 narrows the gap over time.
Which provider offers FDA-approved brand-name medication?
Ro and Hims both offer established paths to FDA-approved Wegovy and Zepbound. MEDVi has recently added brand-name options but is primarily known for compounded products.
Is MEDVi better than Hims?
MEDVi is cheaper on the first month. Hims has a larger customer service operation, fewer billing complaints, a longer track record, and no comparable FDA warning letter. The “better” choice depends on whether you prioritize price or operational maturity.
Why is MEDVi in the news right now?
The NYT profiled MEDVi on April 2, 2026, reporting $401 million in 2025 revenue with two employees and projecting $1.8 billion for 2026. Simultaneously, the company has an FDA warning letter, its clinical partner has a data breach, and pending litigation questions some compounded product efficacy. Both the growth and the controversy are real.
Can I switch from MEDVi to another provider?
Yes. Cancel your MEDVi subscription (72-hour notice required before billing date), then enroll with the new provider. You will need a new intake and clinical evaluation. Tell your new clinician your current dose and treatment duration.
Do any of these providers accept insurance?
None process insurance for compounded GLP-1s. All operate primarily cash-pay. Some accept HSA/FSA. Ro and Hims may assist with insurance paths for brand-name medication, depending on your plan.
This article is for informational purposes only. GLP-1 medications require a prescription. Compounded medications are not FDA-approved finished products. Consult a licensed healthcare professional before starting any medication.
MercyIowaCityClinics.org Editorial Team | Published April 2026